---
layout: post
title: New Drug Approvals 2012 - Pt. I - Glucarpidase (VoraxazeTM)
date: '2012-01-23T11:32:00.000Z'
author: Patricia
tags:
- Parenteral Drugs
- Enzyme drugs
- 2012 New Drugs
modified_time: '2013-01-02T09:30:45.170Z'
thumbnail: http://2.bp.blogspot.com/-USrmhe67fuU/UOP-QK0pfFI/AAAAAAAACkc/6cB7Ie62vTw/s72-c/BTG02100.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-4660469111412574100
blogger_orig_url: http://chembl.blogspot.com/2012/01/new-drug-approvals-2012-pt-i.html
---

<div style="text-align: center;">
</div>
<div style="text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-USrmhe67fuU/UOP-QK0pfFI/AAAAAAAACkc/6cB7Ie62vTw/s1600/BTG02100.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/-USrmhe67fuU/UOP-QK0pfFI/AAAAAAAACkc/6cB7Ie62vTw/s1600/BTG02100.jpg" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/2,0,0,0,1,0,1,0,0" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/2,0,0,0,1,0,1,0,0" width="400" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div style="text-align: center;">
<b>ATC code: <a href="http://www.whocc.no/atc_ddd_index/?code=V03AF09">V03AF09</a></b><br />
<br />
<div style="text-align: left;">
<span class="Apple-style-span">The first FDA new drug approval of 2012 is Glucarpidase, approved on Jan 17th 2012. Glucarpidase (tradename: <a href="http://www.trademarkia.com/trademarks-search.aspx?tn=Voraxaze">Voraxaze</a>; formerly known as carboxypeptidase-G2 or CPG2) is a carboxypeptidase enzyme indicated for the treatment of toxic plasma <a href="http://en.wikipedia.org/wiki/Methotrexate">methotrexate (MTX)</a> concentrations (<span class="Apple-style-span" style="font-family: monospace; white-space: pre;">&gt;</span></span>1 umol/L) in patients with delayed MTX clearance due to impaired renal function.</div>
<div style="text-align: center;">
</div>
<br />
<div style="text-align: left;">
<span class="Apple-style-span">MTX (ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL426">CHEMBL426</a>) is an antifolate drug and is one of the most widely used anticancer agents. Unlike other anticancer agents, MTX <a href="http://theoncologist.alphamedpress.org/content/11/6/694.full">can be</a> safely administrated over a wide dose range. However, during treatment with high doses of MTX, patients may develop renal dysfunction. Since MTX is primarily cleared by renal excretion, this will lead to toxic levels of MTX. </span>Glucarpidase<span class="Apple-style-span"> acts by converting MTX to its inactive metabolites 2,4-diamino-N<sup>10</sup>-methylpteroic acid (DAMPA) and gluta</span>mic acid, providing thus an alternate route of elimination to renal excretion.<br />
<br /></div>
<div style="text-align: left;">
<span class="Apple-style-span"> <img alt="" border="0" id="BLOGGER_PHOTO_ID_5699027866882885186" src="http://3.bp.blogspot.com/-BFTgd6wPE2c/TxcDpnKbRkI/AAAAAAAAAo4/uSvMqD_TAWc/s320/metabolites.png" style="display: block; height: 314px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; text-align: center; width: 320px;" /></span></div>
</div>
Glucarpidase (Uniprot: <a href="http://www.uniprot.org/uniprot/P06621">P06621</a>) is a carboxypeptidase produced by recombinant DNA technology in genetically modified <i>Escherichia coli</i>. Glucarpidase is a 390-amino acid homodimer protein with a molecular weight of 83 kDa. The crystal structure of Glucarpidase is known (PDBe: <a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1cg2/summary">1cg2</a>, homotetramer form).<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-kfO-QrnFN6c/TxcOwgfhwnI/AAAAAAAAApM/sZRPZ7599Ac/s1600/glucarpidase_pdb.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="240" src="http://2.bp.blogspot.com/-kfO-QrnFN6c/TxcOwgfhwnI/AAAAAAAAApM/sZRPZ7599Ac/s320/glucarpidase_pdb.png" width="320" /></a></div>
<br />
<div>
</div>
<div>
<div style="text-align: left;">
<div style="text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<pre><span class="reflink plainlinks nourlexpansion">&gt;Glucarpidase
ALAQKRDNVL FQAATDEQPA VIKTLEKLVN IETGTGDAEG IAAAGNFLEA ELKNLGFTVT
RSKSAGLVVG DNIVGKIKGR GGKNLLLMSH MDTVYLKGIL AKAPFRVEGD KAYGPGIADD
KGGNAVILHT LKLLKEYGVR DYGTITVLFN TDEEKGSFGS RDLIQEEAKL ADYVLSFEPT
SAGDEKLSLG TSGIAYVQVN ITGKASHAGA APELGVNALV EASDLVLRTM NIDDKAKNLR
FNWTIAKAGN VSNIIPASAT LNADVRYARN EDFDAAMKTL EERAQQKKLP EADVKVIVTR
GRPAFNAGEG GKKLVDKAVA YYKEAGGTLG VEERTGGGTD AAYAALSGKP VIESLGLPGF
GYHSDKAEYV DISAIPRRLY MAARLIMDLG AGK</span></pre>
<div>
<div style="text-align: left;">
<span class="Apple-style-span"><br /></span>
<span class="Apple-style-span">The recommended dosage of Glucarpidase is a single intravenous injection of 50 Units/kg.</span><br />
<br />
<span class="Apple-style-span">Glucarpidase has a volume of distribution (Vd) of 3.6 L, a systemic clearance (CL) of 7.5 mL/min and an elimination half-life (t1/2) of 5.6 hours.</span><br />
<br />
<span class="Apple-style-span">The full prescribing information of Voraxaze can be found <a href="http://www.btgplc.com/document/433">here</a>.</span><br />
<br />
<span class="Apple-style-span">The license holder is <a href="http://www.btgplc.com/">BTG international Inc.</a></span></div>
<div style="text-align: center;">
</div>
</div>
</div>
</div>
